|
|
Substance Name: Ticlopidine hydrochloride [USAN:USP:JAN]
RN: 53885-35-1
UNII: A1L4914FMF
InChIKey: MTKNGOHFNXIVOS-UHFFFAOYSA-N
Note
- Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.
Molecular Formula
- C14-H14-Cl-N-S.Cl-H
Molecular Weight
- 300.2515
- All
- Classifications
- Links to Resources
- Names & Synonyms
- Registry Numbers
- Formulas
- Structure Descriptors
- Toxicity
Classification Codes
- Drug / Therapeutic Agent
- Human Data
- Inhibitor (Platelet)
- Reproductive Effect
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Ticlopidine hydrochloride [USAN:USP:JAN]
Synonyms
- 4-C-32
- 5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno-(3,2-c)pyridine hydrochloride
- 53-32C
- EINECS 258-837-4
- NSC 759165
- Panaldine
- Ticlid
- Ticlodix
- Ticlodone
- Ticlopidine HCl
- Ticlopidine hydrochloride
- Tiklid
- UNII-A1L4914FMF
Systematic Names
- 5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridinium chloride
- Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-(o-chlorobenzyl)-, hydrochloride
- Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-, hydrochloride
Registry Numbers
CAS Registry Number
- 53885-35-1
FDA UNII
- A1L4914FMF
System Generated Number
- 0053885351
Molecular Formulas
Molecular Formula
- C14-H14-Cl-N-S.Cl-H
Molecular Formula Fragments
- C14-H14-Cl-N-S
- Cl-H
- COMPONENT
Structure Descriptors
InChI
InChI=1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1HInChIKey
MTKNGOHFNXIVOS-UHFFFAOYSA-NSmiles
Cl.Clc1ccccc1CN2CCc3sccc3C2Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
monkey | LD50 | intraperitoneal | 500mg/kg (500mg/kg) | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. | |
mouse | LD50 | intravenous | 55mg/kg (55mg/kg) | United States Patent Document. Vol. #4051141, | |
mouse | LD50 | oral | 600mg/kg (600mg/kg) | Medical Pharmacy. Vol. 15, Pg. 272, 1981. | |
mouse | LD50 | subcutaneous | 2690mg/kg (2690mg/kg) | Medical Pharmacy. Vol. 15, Pg. 272, 1981. | |
rat | LD50 | intravenous | 70mg/kg (70mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 1204, 1981. | |
rat | LD50 | oral | 1780mg/kg (1780mg/kg) | Medical Pharmacy. Vol. 15, Pg. 272, 1981. | |
rat | LD50 | subcutaneous | > 3gm/kg (3000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakkyoku. Pharmacy. Vol. 32, Pg. 1499, 1981. |
women | LDLo | unreported | 180mg/kg/18D- (180mg/kg) | BLOOD: APLASTIC ANEMIA LIVER: LIVER FUNCTION TESTS IMPAIRED SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | American Journal of Hematology. Vol. 59, Pg. 260, 1998. |
women | TDLo | oral | 49mg/kg/1W-I (49mg/kg) | LIVER: LIVER FUNCTION TESTS IMPAIRED LIVER: "JAUNDICE, CHOLESTATIC" | American Journal of Hospital Pharmacy. Vol. 51, Pg. 1821, 1994. |
women | TDLo | oral | 189mg/kg/17D- (189mg/kg) | LIVER: "JAUNDICE, CHOLESTATIC" LIVER: LIVER FUNCTION TESTS IMPAIRED | American Journal of Hospital Pharmacy. Vol. 51, Pg. 1821, 1994. |
women | TDLo | oral | 1896mg/kg/26W (1896mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING LIVER: "JAUNDICE, CHOLESTATIC" | Clinical Pharmacy. Vol. 12, Pg. 398, 1993. |